Evidence map›Paper›PMID 39925446›Full record

ReviewGlobal medical genetics2025

Cytochrome P450 3A gene family and medication in childhood nephrotic syndrome: An update.

Praveenkumar Kochuthakidiyel Suresh, Yogalakshmi Venkatachalapathy, Sudha Ekambaram, Sangeetha, Megha Manoj, MohanaPriya C D

Abstract readReview
In one paragraph

Review in Global medical genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Praveenkumar Kochuthakidiyel SureshSri Ramachandra Institute of Higher Education and Research, Department of Human Genetics, Chennai, Tamil Nadu 600116, India.
Yogalakshmi VenkatachalapathySri Ramachandra Institute of Higher Education and Research, Department of Human Genetics, Chennai, Tamil Nadu 600116, India.
Sudha EkambaramApollo Children's Hospital, Department of Pediatric Nephrology, 600006, India.
SangeethaSri Ramachandra Institute of Higher Education and Research, Department of Paediatric Medicine, Chennai, Tamil Nadu 600116, India.
Megha ManojSri Ramachandra Institute of Higher Education and Research, Department of Bioinformatics, Chennai, Tamil Nadu 600116, India.
MohanaPriya C DSri Ramachandra Institute of Higher Education and Research, Department of Human Genetics, Chennai, Tamil Nadu 600116, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Nephrotic syndrome (NS) is a renal disease characterized by excessive proteinuria (greater than 3.5 g/dl per 24 h), which results in hypoalbuminemia and leads to hyperlipidemia, edema, and various complications. NS patients typically respond to standard steroid treatment (prednisolone) and are classified as having steroid-sensitive nephrotic syndrome (SSNS). However, patients who do not respond to steroid therapy after 4 weeks are referred to as having steroid-resistant nephrotic syndrome (SRNS). The unequal response to steroid treatment in nephrotic syndrome involved many factors, including genetic, medication, and kidney diseases. The Methodology: A systematic literature review was conducted from January 2014 to June 2024 using an extensive electronic search of data related to pediatric nephrotic syndrome and the CYP gene family, including associated polymorphisms. Through this review, we systematically analyze factors that affect the metabolism of medications targeting the Conclusion: Studies have correlated the relationship between polymorphisms in the

Indexed as

Cytochrome P450Nephrotic syndromeSingle nucleotide polymorphism

Identifiers

PMID39925446
PMCPMC11800309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.